Shandong Pharmaceutical Glass Co., Ltd. Class A

Shandong Pharmaceutical Glass Co., Ltd. Class A

SSSE:600529
18.03
CNY
-0.08
(-0.44%)
1.00EPS
18.11P/E
12.06BMarket Cap
Apr 27Next Earn

Total Valuation

CNY

As of September 30, 2026, Shandong Pharmaceutical Glass Co., Ltd. Class A carries a market capitalization of 12.06B, placing it among publicly traded companies globally. Its enterprise value stands at 9.38B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap12.06B
Enterprise Value9.38B

Important Dates

Shandong Pharmaceutical Glass Co., Ltd. Class A's next confirmed earnings release is scheduled for April 27, 2027.

Earnings Date4/27/2027

Share Statistics

As of September 30, 2026, Shandong Pharmaceutical Glass Co., Ltd. Class A has 663.61M shares outstanding.

Shares Outstanding663.61M

Valuation Ratios

As of September 30, 2026, Shandong Pharmaceutical Glass Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 18.11. The price-to-sales ratio is 2.77, and the price-to-book ratio stands at 1.42.

PE Ratio18.11
PS Ratio2.77
PB Ratio1.42
P/TBV Ratio1.46

Enterprise Valuation

As of September 30, 2026, Shandong Pharmaceutical Glass Co., Ltd. Class A trades at an EV/EBITDA multiple of 11.44 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.15 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 11.44 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 9.38B versus a market cap of 12.06B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales2.15
EV / EBITDA11.44
EV / EBIT11.44

Financial Position

As of September 30, 2026, Shandong Pharmaceutical Glass Co., Ltd. Class A maintains a current ratio of 4.28, meaning it holds 4.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.45, indicating conservative leverage, while an interest coverage ratio of 608.72 demonstrates strong ability to service its debt obligations.

Current Ratio4.28
Quick Ratio1.91
Debt / Equity0.45
Debt / EBITDA0.05
Interest Coverage608.72

Financial Efficiency

CNY

These figures cover the twelve months ended September 30, 2026. The company generates approximately 645,189.84 in revenue per employee across its workforce of 6,775.00, a quick read on workforce productivity versus industry peers.

Revenue Per Employee645,189.84
Employee Count6,775.00

Taxes

CNY

Over the twelve months ended September 30, 2026, Shandong Pharmaceutical Glass Co., Ltd. Class A recorded 143.96M in income tax expense. That works out to an effective tax rate of 17.74, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 811.39M, leaving 667.43M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax143.96M
Effective Tax Rate17.74

Stock Price Statistics

CNY

As of the close on November 17, 2026, Shandong Pharmaceutical Glass Co., Ltd. Class A's stock has declined approximately 14.99% over the past 52 weeks. The 50-day moving average sits at 18.36, while the 200-day moving average is 18.92.

52-Week Price Change-14.99%
50-Day Moving Average18.36
200-Day Moving Average18.92

Income Statement

CNY

Over the twelve months ended September 30, 2026, Shandong Pharmaceutical Glass Co., Ltd. Class A generated 4.37B in revenue and converted that into 667.43M in net income, yielding earnings per share of 1.00. EBITDA reached 819.64M, while operating income came in at 918.20M.

Revenue4.37B
Gross Profit1.42B
Operating Income918.20M
Pretax Income811.39M
Net Income667.43M
EBITDA819.64M
EBIT819.64M
Earnings Per Share (EPS)1.00

Balance Sheet

CNY

As of September 30, 2026, Shandong Pharmaceutical Glass Co., Ltd. Class A holds 2.72B in cash and equivalents against 38.11M in total debt, resulting in a net debt position of -1.01B. Total book value stands at 8.50B, with working capital of 4.67B providing operational flexibility.

Cash & Cash Equivalents2.72B
Total Debt38.11M
Net Debt-1.01B
Equity (Book Value)8.50B
Book Value Per Share12.80
Working Capital4.67B

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-172.36M

Margins

Over the twelve months ended September 30, 2026, Shandong Pharmaceutical Glass Co., Ltd. Class A posted a gross margin of 32.38, reflecting its pricing power and cost economics. The operating margin of 21.01 and net profit margin of 15.27 provide insight into operational efficiency.

Gross Margin32.38
Operating Margin21.01
Pretax Margin18.56
Profit Margin15.27
EBITDA Margin18.75

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Shandong Pharmaceutical Glass Co., Ltd. Class A paid dividends of 0.28 per share. The dividend payout ratio of 28.18 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 2.50, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Shandong Pharmaceutical Glass Co., Ltd. Class A shareholders.

Dividend Per Share0.28
Payout Ratio28.18
Shareholder Yield2.50

Stock Splits

Shandong Pharmaceutical Glass Co., Ltd. Class A's most recent stock split took place on June 20, 2019 with a 5:7 split ratio.

Last Split Date6/20/2019
Split Ratio5:7

Scores

As of September 30, 2026, Shandong Pharmaceutical Glass Co., Ltd. Class A has an Altman Z-Score of 6.58, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score6.58